Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bicycle Therapeutics (BCYC) Invested Capital (2018 - 2025)

Bicycle Therapeutics' Invested Capital history spans 8 years, with the latest figure at $610.0 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 23.09% year-over-year to $610.0 million; the TTM value through Dec 2025 reached $610.0 million, down 23.09%, while the annual FY2025 figure was $610.0 million, 23.09% down from the prior year.
  • Invested Capital reached $610.0 million in Q4 2025 per BCYC's latest filing, down from $618.5 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $896.2 million in Q2 2024 to a low of $142.0 million in Q2 2021.
  • Average Invested Capital over 5 years is $438.4 million, with a median of $351.2 million recorded in 2021.
  • Peak YoY movement for Invested Capital: dropped 29.32% in 2023, then soared 307.19% in 2024.
  • A 5-year view of Invested Capital shows it stood at $346.3 million in 2021, then fell by 21.8% to $270.8 million in 2022, then skyrocketed by 36.98% to $370.9 million in 2023, then skyrocketed by 113.8% to $793.1 million in 2024, then dropped by 23.09% to $610.0 million in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Invested Capital are $610.0 million (Q4 2025), $618.5 million (Q3 2025), and $668.9 million (Q2 2025).